Acute Cognitive Effects of the Dual Orexin Receptor Antagonist Lemborexant Compared With Suvorexant and Zolpidem in Recreational Sedative Users

Ishani Landry, Nancy Hall, Jagadeesh Alur, Gleb Filippov, Larisa Reyderman, Beatrice Setnik, Jack Henningfield, Margaret Moline, Ishani Landry, Nancy Hall, Jagadeesh Alur, Gleb Filippov, Larisa Reyderman, Beatrice Setnik, Jack Henningfield, Margaret Moline

Abstract

Purpose/background: As part of a human abuse potential (HAP) study of lemborexant (LEM), the effects of therapeutic (LEM 10 mg), and supratherapeutic doses of LEM 20 mg and LEM 30 mg on cognition and psychomotor performance were compared with placebo (PBO) and supratherapeutic doses of zolpidem (ZOL) 30 mg and suvorexant (SUV) 40 mg. Subjects (n = 32) were healthy, nondependent, recreational sedative users able to discriminate the effects of both SUV and ZOL from PBO on subjective drug measures.

Methods/procedures: The human abuse potential study was a single-dose, randomized, double-blind, PBO-controlled, 6-way crossover study. Eligible subjects admitted to the treatment phase completed the choice reaction test (CRT) and divided attention test. The CRT included measurements of recognition reaction time (RRT) and motor reaction time.

Findings/results: Recognition reaction time and mean maximum change from baseline (CFB max ) scores were significantly increased (slower performance) versus PBO for all LEM doses (all P < 0.001), ZOL ( P < 0.001), and SUV ( P = 0.004), and LEM (all doses) was not statistically different from ZOL or SUV. Motor reaction time and mean CFB max versus PBO were significantly increased for all LEM doses (all P < 0.001), and ZOL ( P < 0.001) and SUV ( P < 0.001). All LEM doses showed significantly decreased (better performance) mean CFB max versus ZOL (all P < 0.001), but not SUV. Notably, all cognitive effects in the CRT and divided attention test were limited to the main treatment phase (up to 8 hours postdose).

Implications/conclusions: All active doses of LEM, ZOL, and SUV generally increased reaction time and reduced divided attention capabilities versus PBO. However, at therapeutic/supratherapeutic doses, LEM led to significantly less cognitive impairment than supratherapeutic doses of ZOL in some measures.

Trial registration: ClinicalTrials.gov NCT03158025.

Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.

Figures

FIGURE 1
FIGURE 1
Mean CRT over time. A, Recognition reaction time, (B) MRT, and (C) total response time. SUV indicates suvorexant 40 mg; ZOL, zolpidem 30 mg; CRT, Choice Reaction Time; LEM10, lemborexant 10 mg; LEM20, lemborexant 20 mg; LEM30, lemborexant 30 mg; PBO, placebo; SUV, suvorexant 40 mg; ZOL, zolpidem 30 mg.
FIGURE 2
FIGURE 2
Divided attention test over time. A, Root mean square distance and mean DAT over time, (B) greatest distance from center of the road, (C) percent time over road, (D) response latency: correct response, (E) number of false alarms, and (F) percentage of target hits. SUV indicates suvorexant 40 mg; ZOL, zolpidem 30 mg. DAT, divided attention test; LEM10, lemborexant 10 mg; LEM20, lemborexant 20 mg; LEM30, lemborexant 30 mg; PBO, placebo; SUV, suvorexant 40 mg; ZOL, zolpidem 30 mg.

References

    1. Kärppä M Yardley J Pinner K, et al. . Long-term efficacy and tolerability of lemborexant compared with placebo in adults with insomnia disorder: results from the phase 3 randomized clinical trial SUNRISE 2. Sleep. 2020;43.
    1. Rosenberg R Murphy P Zammit G, et al. . Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial. JAMA Netw Open. 2019;2:e1918254.
    1. Beuckmann CT Suzuki M Ueno T, et al. . In vitro and in silico characterization of lemborexant (E2006), a novel dual orexin receptor antagonist. J Pharmacol Exp Ther. 2017;362:287–295.
    1. Food and Drug Administration . Assessment of Abuse Potential of Drugs: Guidance for Industry. Available at: . Accessed September 24, 2020.
    1. Gould TJ. Addiction and cognition. Addict Sci Clin Pract. 2010;5:4–14.
    1. Schoedel KA Sun H Sellers EM, et al. . Assessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover study. J Clin Psychopharmacol. 2016;36:314–323.
    1. Landry I, Hall H, Aluri J, Filippov G, Reyderman L, Setnik B, Henningfield J, Moline M. Abuse potential of lemborexant, a dual orexin receptor antagonist, compared with zolpidem and suvorexant in recreational sedative users. J Clin Psychopharmacol. 2022;42:363–373.
    1. Ferrara SD Giorgetti R Zancaner S, et al. . Effects of single dose of gamma-hydroxybutyric acid and lorazepam on psychomotor performance and subjective feelings in healthy volunteers. Eur J Clin Pharmacol. 1999;54:821–827.
    1. Gustavsen I Hjelmeland K Bernard JP, et al. . Individual psychomotor impairment in relation to zopiclone and ethanol concentrations in blood—a randomized controlled double-blinded trial. Addiction 2012;107:925–932.
    1. Jones JD Bisaga A Metz VE, et al. . The PPARgamma agonist pioglitazone fails to alter the abuse potential of heroin, but does reduce heroin craving and anxiety. J Psychoactive Drugs. 2018;50:390–401.
    1. Levy-Cooperman N Schoedel KA Chakraborty B, et al. . Abuse liability assessment of eslicarbazepine acetate in healthy male and female recreational sedative users: a phase I randomized controlled trial. Epilepsy Behav. 2016;61:63–71.
    1. Hindmarch I Rigney U Stanley N, et al. . Pharmacodynamics of milnacipran in young and elderly volunteers. Br J Clin Pharmacol. 2000;49:118–125.
    1. Kaplan HL. Representation of on-line questionnaires in an editable, auditable database. Behav Res Methods Instrum Comput. 1992;24:373–384.
    1. Atkin T, Comai S, Gobbi G. Drugs for insomnia beyond benzodiazepines: pharmacology, clinical applications, and discovery. Pharmacol Rev. 2018;70:197–245.
    1. Ueno T Ishida T Aluri J, et al. . Disposition and metabolism of [(14)C]lemborexant in healthy human subjects and characterization of its circulating metabolites. Drug Metab Dispos. 2021;49:31–38.
    1. Moline M Zammit G Yardley J, et al. . Lack of residual morning effects of lemborexant treatment for insomnia: summary of findings across 9 clinical trials. Postgrad Med. 2021;133:71–81.
    1. Landry I Hall N Aluri J, et al. . Effect of alcohol coadministration on the pharmacodynamics, pharmacokinetics, and safety of lemborexant. American College of Neuropsychopharmacology Congress; December 8–11, 2019; Orlando, FL.
    1. Vermeeren A Jongen S Murphy P, et al. . On-the-road driving performance the morning after bedtime administration of lemborexant in healthy adult and elderly volunteers. Sleep. 2019;42.
    1. Cruz HG Hoever P Chakraborty B, et al. . Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. CNS Drugs. 2014;28:361–372.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren